Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 101 recruiting now early-phase tilt #33 of 28,707 conditions

Pancreatic Cancer: early-phase trial registry

101 of 283 indexed Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #33 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

283 US clinical trials · 101 currently recruiting · #33 of 28,707 conditions by registered trial count

Pancreatic Cancer: 283 US clinical trials tracked, 101 recruiting.

Pancreatic Cancer is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 101 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 180 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 19 of these trials.

Enrollment posture brief

Registry condition pancreatic-cancer

OPEN 101 | RECR 36% | LATE 12 | EARLY 180 | RANK #33 | SPON 19

Volume-matched condition peers

Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)

Major Depressive Disorder38.5%Pancreatic Cancer (this)36%Melanoma33.1%Healthy Volunteers27.8%Leukemia18.6%
Open-enrollment share among volume-matched conditions near Pancreatic Cancer

Pancreatic Cancer lists 101 open slots (36% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pancreatic Cancer recruits in line with its size-band peers.

    101 of 283 indexed trials (35.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Pancreatic Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 19 of 283 trials (6.7%). 165 distinct sponsors appear on at least one study for this condition label.

  3. Most Pancreatic Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 279 trials that report a genuine target (sentinel values excluded). 170 of those (60.9%) plan for fewer than 100 participants.

  4. Pancreatic Cancer research is mostly interventional.

    237 interventional and 46 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1114Phase 266Phase 310Phase 42

Open and recent trials

283 total, page 3 of 6

RECRUITING Phase 2 10 participants

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Gulam Manji

NCT04543071
ACTIVE NOT RECRUITING 6,000 participants

Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

Memorial Sloan Kettering Cancer Center

NCT00582647
ACTIVE NOT RECRUITING 1,000 participants

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

NCT05179824
ACTIVE NOT RECRUITING Phase 1 702 participants

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

AstraZeneca

NCT04644068
ACTIVE NOT RECRUITING Phase 2 534 participants

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Hoffmann-La Roche

NCT02568267
ACTIVE NOT RECRUITING Phase 3 501 participants

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Revolution Medicines

NCT06625320
ACTIVE NOT RECRUITING 500 participants

Florida Pancreas Collaborative Next Generation Biobank

H. Lee Moffitt Cancer Center and Research Institute

NCT03851133
ACTIVE NOT RECRUITING Phase 1 466 participants

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Nuvation Bio

NCT06334432
ACTIVE NOT RECRUITING Phase 2 393 participants

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Astellas Pharma Global Development

NCT03816163
ACTIVE NOT RECRUITING Phase 3 358 participants

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Alliance for Clinical Trials in Oncology

NCT04340141
ACTIVE NOT RECRUITING Phase 2 350 participants

9-ING-41 in Patients with Advanced Cancers

Actuate Therapeutics

NCT03678883
ACTIVE NOT RECRUITING Phase 2 328 participants

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

ImmunityBio

NCT04390399
ACTIVE NOT RECRUITING NA 300 participants

Supportive Oncology Care At Home RCT

Massachusetts General Hospital

NCT04544046
ACTIVE NOT RECRUITING 271 participants

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

Dana-Farber Cancer Institute

NCT03060720
ACTIVE NOT RECRUITING NA 205 participants

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

M.D. Anderson Cancer Center

NCT05677048
ACTIVE NOT RECRUITING Phase 2 194 participants

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics

NCT06119217
ACTIVE NOT RECRUITING Phase 1 180 participants

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Poseida Therapeutics

NCT05239143
ACTIVE NOT RECRUITING Phase 2 168 participants

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Massachusetts General Hospital

NCT03563248
ACTIVE NOT RECRUITING Phase 1 160 participants

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

A2 Biotherapeutics

NCT05736731
ACTIVE NOT RECRUITING NA 152 participants

PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer

M.D. Anderson Cancer Center

NCT03187951
ACTIVE NOT RECRUITING Phase 1 150 participants

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co.

NCT04396821
ACTIVE NOT RECRUITING Phase 1 137 participants

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

ENB Therapeutics

NCT04205227
ACTIVE NOT RECRUITING NA 133 participants

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

Viewray

NCT03621644
ACTIVE NOT RECRUITING Phase 1 130 participants

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals

NCT05215574
ACTIVE NOT RECRUITING NA 110 participants

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Memorial Sloan Kettering Cancer Center

NCT02921022
ACTIVE NOT RECRUITING Phase 1 110 participants

Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

CARsgen Therapeutics Co.

NCT04404595
ACTIVE NOT RECRUITING NA 107 participants

RCT of Mobile Apps & FitBit v. Usual Care

Weill Medical College of Cornell University

NCT03623464
ACTIVE NOT RECRUITING 103 participants

A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer

Mayo Clinic

NCT03902600
ACTIVE NOT RECRUITING 100 participants

Pancreatic Cancer Early Detection Program

White Plains Hospital

NCT02206360
ACTIVE NOT RECRUITING Phase 1 98 participants

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics

NCT05864144
ACTIVE NOT RECRUITING NA 95 participants

Exercise and Nutrition to Improve Pancreatic Cancer Outcomes

University of Oklahoma

NCT03256201
ACTIVE NOT RECRUITING Phase 2 84 participants

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Massachusetts General Hospital

NCT03104439
ACTIVE NOT RECRUITING NA 80 participants

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

H. Lee Moffitt Cancer Center and Research Institute

NCT05675059
ACTIVE NOT RECRUITING Phase 1 76 participants

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

XBiotech

NCT04825288
ACTIVE NOT RECRUITING Phase 2 76 participants

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02451982
ACTIVE NOT RECRUITING 74 participants

Predicting Effective Therapy in Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT03033927
ACTIVE NOT RECRUITING Phase 2 71 participants

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01088789
ACTIVE NOT RECRUITING Phase 1 71 participants

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals

NCT05311618
ACTIVE NOT RECRUITING Phase 3 58 participants

Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer

M.D. Anderson Cancer Center

NCT05836870
ACTIVE NOT RECRUITING Phase 1 56 participants

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Legend Biotech USA

NCT05539430
ACTIVE NOT RECRUITING 55 participants

A Study of the Life Changes Experienced by Patients With Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT04427761
ACTIVE NOT RECRUITING Phase 2 53 participants

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology

NCT05945823
ACTIVE NOT RECRUITING NA 50 participants

Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT05438927
ACTIVE NOT RECRUITING Phase 2 47 participants

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT03523312
ACTIVE NOT RECRUITING Phase 1 42 participants

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

HUYABIO International

NCT05163028
ACTIVE NOT RECRUITING NA 40 participants

The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response

H. Lee Moffitt Cancer Center and Research Institute

NCT06050395
ACTIVE NOT RECRUITING Phase 2 32 participants

Niraparib in Patients With Pancreatic Cancer

Dana-Farber Cancer Institute

NCT03601923
ACTIVE NOT RECRUITING NA 32 participants

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

Milton S. Hershey Medical Center

NCT06384417
ACTIVE NOT RECRUITING Phase 2 30 participants

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

Massachusetts General Hospital

NCT04361162
ACTIVE NOT RECRUITING Phase 2 30 participants

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

University of Arizona

NCT04820179
← Previous Page 3 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 114
Phase 2 66
Phase 3 10
Phase 4 2

Top Sponsors

Memorial Sloan Kettering Cancer Center 19 trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 14 trials
H. Lee Moffitt Cancer Center and Research Institute 11 trials
M.D. Anderson Cancer Center 11 trials
Dana-Farber Cancer Institute 9 trials
Massachusetts General Hospital 6 trials
Washington University School of Medicine 5 trials
National Cancer Institute (NCI) 5 trials
Eli Lilly and Company 4 trials
City of Hope Medical Center 4 trials

Named interventions

Most-linked intervention names on Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Gemcitabine Drug
20 trials
Cyclophosphamide Drug
10 trials
gemcitabine hydrochloride Drug
7 trials
Nivolumab Drug
6 trials
Pembrolizumab Drug
6 trials
erlotinib hydrochloride Drug
5 trials
Irinotecan Drug
5 trials
Oxaliplatin Drug
5 trials

US sites by state

Facility locations filed on Pancreatic Cancer trials. A trial with sites in several states counts in each.

New York 74 trials
California 72 trials
Florida 67 trials
Texas 62 trials
Massachusetts 43 trials
Maryland 38 trials
Michigan 35 trials
Arizona 32 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Pancreatic Cancer page

283 registered trials, 101 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer condition card totals 283 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.